Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

High-throughput profiling of human castration-resistant prostate cancer cell lines

ABSTRACT: This SuperSeries is composed of the SubSeries listed below.

ORGANISM(S): Homo sapiens

PROVIDER: GSE154576 | GEO | 2020/07/17

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

High-throughput gene expression profiling of human castration-resistant prostate cancer cell lines

Project description:We examine the gene expression and chromatin accessibility profiles of four human castration-resistant prostate cancer cell lines including two representative of small-cell neuroendocrine prostate cancer

2020-07-17 | GSE154575 | GEO

High-throughput chromatin accessibility profiling of human castration-resistant prostate cancer cell lines

2020-07-17 | GSE154574 | GEO

High-throughput profiling of human castration-resistant prostate cancer cell lines

Project description:High-throughput profiling of human castration-resistant prostate cancer cell lines

| PRJNA646715 | ENA

LSD1 promotes castration-resistant prostate cancer progression

Project description:This SuperSeries is composed of the SubSeries listed below. Refer to individual Series

2016-06-30 | E-GEOD-77763 | biostudies-arrayexpress

Targeting the MLL complex in castration-resistant prostate cancer

Project description:This SuperSeries is composed of the SubSeries listed below. Refer to individual Series

2015-02-27 | E-GEOD-60842 | biostudies-arrayexpress

Cytokine profiling of docetaxel-resistant castration-resistant prostate cancer.

Project description:BackgroundDocetaxel improves symptoms and survival in metastatic castration-resistant prostate cancer (CRPC). However, ?50% of patients are chemoresistant. This study examined whether changes in cytokine levels predict for docetaxel resistance in vitro and in a clinical cohort.MethodsPC3 cells or their docetaxel-resistant subline (PC3Rx) were co-cultured with U937 monocytes, with and without docetaxel treatment, and cytokine levels were measured. The circulating levels of 28 cytokines were measured pre-/post cycle 1 of docetaxel from 55 men with CRPC, and compared with prostate-specific antigen (PSA) response.ResultsPC3Rx-U937 co-culture expressed more cytokines, chiefly markers of alternative macrophage differentiation, compared with PC3-U937 co-culture. Docetaxel treatment enhanced cytokine production by PC3Rx-U937 co-culture, while reducing cytokine levels in PC3-U937. In patients, changes in the levels of seven circulating cytokines (macrophage inhibitory cytokine 1 (MIC1), interleukin (IL)-1ra, IL-1?, IL-4, IL-6, IL-12 and IFN?) after cycle 1 of docetaxel were associated with progressive disease (all P<0.05). The combination of changes in MIC1, IL-4 and IL-6 most strongly predicted PSA response (P=0.002).ConclusionsIn vitro studies suggest docetaxel resistance is mediated, at least in part, by cytokines induced by the interaction between the docetaxel-resistant tumour cells and macrophages. Early changes in circulating cytokine levels were associated with docetaxel resistance in CRPC patients. When considered together, these data suggest a significant role for the inflammatory response and macrophages in the development of docetaxel resistance in CRPC.

| S-EPMC4402456 | biostudies-literature

Integrated high-throughput analysis identifies super enhancers in metastatic castration-resistant prostate cancer.

Project description:Background: Metastatic castration-resistant prostate cancer (mCRPC) is a highly aggressive stage of prostate cancer, and non-mutational epigenetic reprogramming plays a critical role in its progression. Super enhancers (SE), epigenetic elements, are involved in multiple tumor-promoting signaling pathways. However, the SE-mediated mechanism in mCRPC remains unclear. Methods: SE-associated genes and transcription factors were identified from a cell line (C4-2B) of mCRPC by the CUT&Tag assay. Differentially expressed genes (DEGs) between mCRPC and primary prostate cancer (PCa) samples in the GSE35988 dataset were identified. What's more, a recurrence risk prediction model was constructed based on the overlapping genes (termed SE-associated DEGs). To confirm the key SE-associated DEGs, BET inhibitor JQ1 was applied to cells to block SE-mediated transcription. Finally, single-cell analysis was performed to visualize cell subpopulations expressing the key SE-associated DEGs. Results: Nine human TFs, 867 SE-associated genes and 5417 DEGs were identified. 142 overlapping SE-associated DEGs showed excellent performance in recurrence prediction. Time-dependent receiver operating characteristic (ROC) curve analysis showed strong predictive power at 1 year (0.80), 3 years (0.85), and 5 years (0.88). The efficacy of his performance has also been validated in external datasets. In addition, FKBP5 activity was significantly inhibited by JQ1. Conclusion: We present a landscape of SE and their associated genes in mCPRC, and discuss the potential clinical implications of these findings in terms of their translation to the clinic.

| S-EPMC10244677 | biostudies-literature

LSD1 promotes castration-resistant prostate cancer progression

Project description:This SuperSeries is composed of the SubSeries listed below.

2016-06-30 | GSE77763 | GEO

High-throughput chromatin accessibility profiling of human castration-resistant prostate cancer cell lines

Project description:High-throughput chromatin accessibility profiling of human castration-resistant prostate cancer cell lines

| PRJNA646718 | ENA

High-throughput gene expression profiling of human castration-resistant prostate cancer cell lines

Project description:High-throughput gene expression profiling of human castration-resistant prostate cancer cell lines

| PRJNA646717 | ENA